The Fort Worth Press - Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024

USD -
AED 3.672499
AFN 64.49532
ALL 82.224051
AMD 357.911109
ANG 1.790403
AOA 918.000021
ARS 1552.256096
AUD 1.48804
AWG 1.8
AZN 1.69948
BAM 1.778889
BBD 2.013452
BDT 124.862431
BGN 1.77347
BHD 0.377187
BIF 3006.125762
BMD 1
BND 1.288366
BOB 11.661285
BRL 5.777676
BSD 0.999695
BTN 93.389482
BWP 13.993424
BYN 3.000114
BYR 19600
BZD 2.010633
CAD 1.43155
CDF 2294.000032
CHF 0.841101
CLF 0.025261
CLP 994.190154
CNY 6.66615
CNH 6.66667
COP 3309.02
CRC 445.311541
CUC 1
CUP 23.992906
CVE 100.292423
CZK 22.183698
DJF 178.024567
DKK 6.80575
DOP 60.539085
DZD 137.126103
EGP 53.717301
ERN 15
ETB 164.079674
EUR 0.91045
FJD 2.297898
FKP 0.756582
GBP 0.758005
GEL 2.590328
GGP 0.756582
GHS 11.730947
GIP 0.756582
GMD 73.999793
GNF 8857.115571
GTQ 7.640288
GYD 209.05242
HKD 7.84588
HNL 26.876953
HRK 6.831965
HTG 130.972791
HUF 334.197972
IDR 18261
ILS 3.25496
IMP 0.756582
INR 93.383599
IQD 1515.562185
IRR 1929053.495888
ISK 124.559821
JEP 0.756582
JMD 158.860526
JOD 0.709022
JPY 159.281503
KES 130.009768
KGS 87.448974
KHR 4078.347196
KMF 448.000466
KPW 900.00035
KRW 1333.174995
KWD 0.31154
KYD 0.833136
KZT 443.84516
LAK 22515.803356
LBP 89525.524706
LKR 332.648142
LRD 167.946083
LSL 16.912988
LTL 2.95274
LVL 0.60489
LYD 6.460474
MAD 9.977716
MDL 18.305023
MGA 4547.687046
MKD 56.049279
MMK 2099.387164
MNT 3606.75335
MOP 8.079605
MRU 40.508252
MUR 47.940267
MVR 15.407189
MWK 1733.487348
MXN 18.452625
MYR 4.125803
MZN 63.898187
NAD 16.912757
NGN 1351.249652
NIO 36.790956
NOK 9.643395
NPR 149.424033
NZD 1.821739
OMR 0.384491
PAB 0.999682
PEN 3.414253
PGK 4.497642
PHP 63.69303
PKR 276.397058
PLN 4.01095
PYG 6228.540504
QAR 3.644326
RON 4.869696
RSD 107.112027
RUB 82.198852
RWF 1479.544504
SAR 3.760904
SBD 8.137041
SCR 13.848963
SDG 601.512404
SEK 10.144025
SGD 1.289635
SHP 0.757117
SLE 22.802556
SLL 20969.503664
SOS 571.283045
SRD 37.437996
STD 20697.981008
STN 22.283565
SVC 8.747021
SYP 13002.000337
SZL 16.91126
THB 33.896241
TJS 9.212201
TMT 3.5
TND 3.02519
TOP 2.40776
TRY 50.441103
TTD 6.768777
TWD 32.949699
TZS 2649.998023
UAH 45.318338
UGX 4148.305798
UYU 40.61103
UZS 12014.188913
VES 915.501903
VND 25681.5
VUV 121.064676
WST 2.823281
XAF 597.216204
XAG 0.021749
XAU 0.000264236047
XCD 2.70255
XCG 1.801703
XDR 0.707052
XOF 597.216204
XPF 108.472418
YER 236.550068
ZAR 16.980975
ZMK 9001.198131
ZMW 20.479237
ZWL 321.999592
SSP 5928.707524
MXV 2.069558
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024

Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2024.

Text size:

Revenue for the quarter ended September 30, 2024 was $13.6 million compared to $12.9 million for the quarter ended September 30, 2023, an increase of $0.7 million or approximately 5.4%. The Company had operating income for the quarter ended September 30, 2024 of approximately $0.5 million compared to an operating loss of approximately $54,000 for the quarter ended September 30, 2023.

For the quarter ended September 30, 2024, the Company had net income of approximately $0.3 million or $0.01 per share of common stock, compared with a net loss of $59,000 or $0.00 per share of common stock for the quarter ended September 30, 2023. The Company's diluted net income (loss) per share of common stock for the quarters ended September 30, 2024 and 2023 were $0.01 and $0.00 per share of common stock, respectively.

"Our revenue increased by approximately 5% in the quarter ended September 30, 2024 from the quarter ended September 30, 2023 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 85% and 91% of total revenue in the quarters ended September 30, 2024 and 2023, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "Our goal of diversifying our customer base is reflected in our September quarter numbers from 91% in 2023 to 85% in 2024. We hope to continue this trend as well as grow with our current customers," the Co-CEOs further stated.

A summary of our financial results for the three months ended September 30, 2024 and 2023 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)

Three Months Ended

September 30,

2024

2023

Total revenue

$

13,617

$

12,915

Cost of sales

12,246

12,083

Gross profit

1,371

832

Selling and administrative expenses

881

886

Operating income (loss)

490

(54

)

Interest income, net

14

8

Income (loss) before income taxes

504

(46

)

Income tax expense, net

245

13

Net income (loss)

$

259

$

(59

)

Basic net income (loss) per common share

$

0.01

$

(0.00

)

Diluted net income (loss) per common share

$

0.01

$

(0.00

)

Weighted average common shares outstanding -basic

30,099,610

29,965,914

Weighted average common shares outstanding -diluted

30,649,977

29,965,914

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation and the tightened labor markets; the impact of the war in Ukraine; the impact of the Israel-Hamas war; the threat of an East Coast port strike; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
[email protected]
888.319.6962

SOURCE: Integrated BioPharma, Inc.

C.M.Harper--TFWP